Biotech Firm With 650% Return Is Norway’s Best Stock This Year
(Bloomberg) -- ArcticZymes Technologies ASA, a Norwegian biotechnology company, has seen its share price jump 650% so far this year as it benefits from the pharmaceutical industry's Covid-19 efforts, making it the Nordic country's best-performing stock in 2020.
The company, based in Tromso on Norway's northwest coast, extended its surge on Thursday after it said it would supply materials for a possible vaccine against Covid-19. Its shares closed 20% higher in Oslo, the biggest increase in more than two months.
ArcticZymes, which last month changed its name from Biotech Pharmacon, searches for enzymes in the Arctic waters and then uses them to help develop products that are used in molecular research, diagnostics and therapeutics, according to its website.
The company, which now has a market value of about 1.7 billion kroner ($178 million), implemented a new strategy this year, focusing on its enzymes business and vowing to make profits after years of losses.
The company more than doubled sales in the first quarter, driven by deliveries for the development of coronavirus tests. That led to a 52% increase in its share price on April 23, its biggest jump in a single day this year.
©2020 Bloomberg L.P.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
